Grenoble Alps University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Grenoble France (1339)

Organization Overview

First Clinical Trial
2013
NCT03598582
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CHU Grenoble Alpes | Clinical pharmacology unit, grenoble alpes university hospital | EFCR Department and Sleep Laboratory, Grenoble Alpes University Hospital | Grenoble Alpes University Hospital | IDEX - Univ. Grenoble-Alpes | Laboratoire SENS, Univ. Grenoble-Alpes | Métropole Grenoble-Alpes | Université Grenoble Alpes | Université Grenoble Alpes, LIP/PC2S, EA 4145, Grenoble

Active Ingredients

Drugs in Phase 4 Trials (1)

epoetin (Epogen) (1 trial)

Drugs in Phase 3 Trials (1)

human factor ix complex (prothrombin complex concentrate) (Kcentra) (1 trial)

Drugs in Phase 2 Trials (2)

evolocumab (repatha) (1 trial)

treprostinil (remodulin) (2 trials)

Drugs in Phase 1 Trials (1)

99mtccabvcam1-5 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 2)

Cardiovascular Diseases (Phase 2)

Coronary Artery Disease (Phase 2)

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Hemorrhage (Phase 3)

Ischemia (Phase 2)

Myelodysplastic Syndromes (Phase 4)

Myocardial Ischemia (Phase 2)

Preleukemia (Phase 4)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Shock, Hemorrhagic (Phase 3)

Skin Ulcer (Phase 2)

Syndrome (Phase 4)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 5